August 2021 - PsychedelicNewsWire (PNW)

TuesdayAug 31, 2021 2:00 pm

University of Wisconsin-Madison Launches Psychedelics Research Center

At the start of the week, the School of Pharmacy at the University of Wisconsin-Madison unveiled its psychedelics center, named the Transdisciplinary Center for Research in Psychoactive Substances. Researchers will investigate the therapeutic potential of psychedelics like MDMA and psilocybin in treating conditions such as opioid addiction, major depressive disorder and post-traumatic stress disorder. In addition to this, the center will also offer educational training for psychedelics practitioners and scientists. In its press release, the department asserted that the institute would work to consider diversity participants used in research, noting that people of color were often underrepresented in psychedelics studies.…

MondayAug 30, 2021 2:30 pm

Study Finds That Most Mental Health Service Users Support Psychedelics Research

A study that was recently published in the “Irish Journal of Medical Science” has found that individuals who use mental health services in Ireland favorably view research on psychedelics. The study found that more than half of its participants were willing to try psychedelic therapy if their physicians recommended it. However, the study also found evidence of therapeutic misalignment as the symptoms of some individuals who suffer from mental health disorders could be worsened by psychedelics. For the study, the researchers conducted a survey that assessed the attitudes of individuals who suffered from mental health diseases towards psilocybin therapy and…

MondayAug 30, 2021 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Applications to Support Research Phase Programs, Strengthen IP Portfolio

Company’s nonprovisional patent application includes claims to compositions, methods to support certain elements of preclinical and research programs Two international patent applications will grant Cybin the right to file future national applications into treaty member jurisdictions Cybin portfolio consists of 14 patent filings, 50-plus proprietary molecules, 50-plus preclinical studies and 4 active drug programs Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, is moving forward to progress and strengthen its IP portfolio by filing three patents this month. After receiving an international search report of its May 2021 Patent Cooperation Treaty (“PCT”) application, Cybin…

FridayAug 27, 2021 1:32 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), At the Forefront of the Psychedelic Renaissance

Psychedelics date back to ancient times, with records showing their use among the Aztecs as well as cultures in North Africa and Europe for medicinal and cultural purposes The prohibition era marked significant strides in psychedelics research, including the ultimate prohibition of the possession, sale and manufacture of psychedelics The 21st century has seen a surge in psychedelics research, a critical factor that has initiated a renaissance in this industry Tryp Therapeutics remains at the forefront of this renaissance with its commitment to identifying and developing clinical-stage compounds for diseases with high unmet medical needs, like Fibromyalgia and Eating Disorder…

FridayAug 27, 2021 1:30 pm

Portland Activists Call for Psychedelics to Be Decriminalized

Activists in Portland are calling for the city commission to approve a measure that would decriminalize the ceremonial use, gifting and growing of a number of psychedelics. This new measure would make community-based ceremonies and activities that involve entheogenic substances such as ibogaine and ayahuasca among the lowest law-enforcement priorities in Portland, Oregon. The activists, who are part of the PMHA (Plant Medicine Healing Alliance), worked with indigenous groups to draw up the initiative. This is why DMT extracted from toads and peyote were excluded from the initiative because of sustainability concerns. According to an overview, the draft initiative would…

ThursdayAug 26, 2021 1:50 pm

What To Know Before Investing in the Psychedelic Industry

The burgeoning marijuana industry has presented numerous investment opportunities for individuals and companies alike. The psychedelic drug market, which is still immature, seems to be following this trend, with projections showing that its market size will have reached almost $11 billion by 2027. Most analysts agreewith a capital markets analyst from Canaccord Genuity, who estimates that psychedelic substances such as LSD and psilocybin could create an investment opportunity worth nearly $100 billion. Data from the CDC shows that the number of Americans suffering from suicidal thoughts, depression and anxiety almost doubled during the coronavirus pandemic. Numerous studies have also shown…

WednesdayAug 25, 2021 12:45 pm

Psychedelic Clinical Trials in Europe to Advance Through Partnership with CROs

A new dawn in psychedelic research seems to be upon the pharmaceutical industry as we are witnessing partnerships between drug-development companies and contract research organizations. The partnerships are intended to speed up the drug-development process. For example, a partnership between Transpharmation and Clerkenwell Health will facilitate the advancement of psychedelic research in Europe as it will enable both clinical and preclinical trials to run simultaneously. It will also offer opportunities to drug developers working to bring psychedelic-inspired drugs to the market. In addition, such partnerships will provide coordinated and integrated methodology and support for every stage of psychedelic research. The…

TuesdayAug 24, 2021 2:15 pm

Four Fungi Facts Revealed by Netflix Psychedelics Documentary

Psychedelics have become increasingly popular in the last few years as more studies on the substances are conducted by research institutions around the world. The most popular of these substances are LSD, MDMA and psilocybin mushrooms. If you’re yearning to know more about these substances and mushrooms and other fungi in general, but aren’t keen on reading papers in peer review journals, Netflix may be of use to you. The subscription-based streaming service has a documentary, titled “Fantastic Fungi.” that talks about different fungi, The documentary reveals interesting things about mushrooms, some of which aren’t commonly known. For instance, did…

MondayAug 23, 2021 3:30 pm

Five Medical Benefits of Psychedelics

Research on psychedelics has found that the substances could be effectively used to treat various mental health conditions, including post-traumatic stress disorder and anxiety. But, what other therapeutic and medical benefits do psychedelics possess that may help humanity? Making organ transplants safer Ischemia-reperfusion injury, commonly referred to as IRI, occurs when organ tissues are damaged after being deprived of oxygen for some time. The inury can affect organs such as the brain, kidneys, lungs and the heart, and it mainly plagues patients who have undergone organ transplants. Physicians use machine perfusion and ischemic pre- and post-conditioning to reduce or prevent…

MondayAug 23, 2021 10:44 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2021 Operational, Financial Report

Q1 2021 report notes distinction of becoming first psychedelic company to list on the NYSE American LLC stock exchange Cybin has garnered “a great deal of attention as an emerging leader in the psychedelic therapeutics space,” says CEO Several of the quarter’s highlights tied into the company’s active development of its psychedelic pipeline Cybin (NEO: CYBN) (NYSE American: CYBN) is wrapping up a highly successful first quarter with the release of its Q1 2021 operational and financial report, for the period ended June 30, 2021 (https://ibn.fm/V9xNp). The biotech company, which is focused on progressing psychedelic therapeutics, hit some milestones this quarter,…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050

Month: August 2021